Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes - PubMed (original) (raw)

Clinical Trial

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

Anny H Xiang et al. Diabetes. 2006 Feb.

Abstract

The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate beta-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study. Women who completed the TRIPOD study were offered participation in the PIPOD study for a planned 3 years of drug treatment and 6 months of postdrug washout. Oral glucose tolerance tests were performed annually on pioglitazone and at the end of the postdrug washout. Intravenous glucose tolerance tests (IVGTTs) for assessment of insulin sensitivity and beta-cell function were conducted at baseline, after 1 year on pioglitazone, and at the end of the postdrug washout. Of 95 women who were not diabetic at the end of the TRIPOD study, 89 enrolled in the PIPOD study, 86 completed at least one follow-up visit, and 65 completed all study visits, including the postdrug tests. Comparison of changes in beta-cell compensation for insulin resistance across the TRIPOD and PIPOD studies revealed that pioglitazone stopped the decline in beta-cell function that occurred during placebo treatment in the TRIPOD study and maintained the stability of beta-cell function that had occurred during troglitazone treatment in the TRIPOD study. The risk of diabetes, which occurred at an average rate of 4.6% per year, was lowest in women with the largest reduction in total IVGTT insulin area after 1 year of treatment. The similarity of findings between the PIPOD and TRIPOD studies support a class effect of thiazolidinedione drugs to enhance insulin sensitivity, reduce insulin secretory demands, and preserve pancreatic beta-cell function, all in association with a relatively low rate of type 2 diabetes, in Hispanic women with prior gestational diabetes.

PubMed Disclaimer

Figures

FIG. 1

FIG. 1

Relationship between initial fractional reduction in IVGTT insulin area and corresponding diabetes incidence rates in the troglitazone arm of the TRIPOD study (•) and in the PIPOD study (▪). Insulin output was assessed as the total area under the insulin curve during IVGTTs. Reductions in output were calculated between enrollment into each study and the initial on-treatment IVGTT, which occurred after 3 months in the TRIPOD study and after 1 year in the PIPOD study. Symbols represent the low, middle, and high tertile of change in each study. Lines represent best linear fits of data for each study.

Similar articles

Cited by

References

    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement) Diabetes Care. 2004;27 (Suppl 1):S5–S10. - PubMed
    1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–794. - PMC - PubMed
    1. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925–929. - PubMed
    1. Goldfine AB, Bouche C, Parker RA, Kim C, Kerivan A, Soeldner JS, Martin BC, Warram JH, Kahn CR. Insulin resistance is poor predictor of type 2 diabetes in individuals with no family history of disease. Proc Natl Acad Sci U S A. 2003;100:2724–2729. - PMC - PubMed
    1. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican Americans. Diabetes. 1995;44:1386–1391. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources